Accelerated approval might soon be in the cards for COVID-19 vaccines if an immune correlate of protection can be identified through ongoing work by FDA and NIH. Meanwhile, to speed more vaccines to Americans, FDA is trying to help ramp up manufacturing. Sanofi is set to commence a Phase IIb trial with an active comparator.
Top US government officials are optimistic they might soon have data on immune correlates of protection that could allow future COVID-19 vaccine trials to be smaller and curtailed.
The US Food and Drug Administration in conjunction with the National Institutes of Health and drug companies will be working...